Levodopa in the treatment of Parkinson’s disease: an old drug still going strong
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Levodopa in the treatment of Parkinson’s disease: an old drug still going strong Werner Poewe1, Angelo Antonini2, Jan CM Zijlmans3, Pierre R Burkhard4, François Vingerhoets51Department of Neurology, Medical University of Innsbruck, Austria; 2Parkinson Department, IRCCS San Camillo, Venice, and University of Padua, Italy; 3Department of Neurology, Amphia Hospital, Breda, The Netherlands; 4Department of Neurology, Faculty of Medicine and University Hospitals of Geneva, Switzerland; 5Neurodegenerative Disorders Unit, Neurology Department, CHUV, Lausanne, SwitzerlandAbstract: After more than 40 years of clinical use, levodopa (LD) remains the gold standard of symptomatic efficacy in the drug treatment of Parkinson’s disease (PD). Compared with other available dopaminergic therapies, dopamine replacement with LD is associated with the greatest improvement in motor function. Long-term treatment with LD is, however, often complicated by the development of various types of motor response oscillations over the day, as well as drug-induced dyskinesias. Motor fluctuations can be improved by the addition of drugs such as entacapone or monoamine oxidase inhibitors, which extend the half-life of levodopa or dopamine, respectively. However, dyskinesia control still represents a major challenge. As a result, many neurologists have become cautious when prescribing therapy with LD. This review summarizes the available evidence regarding the use of LD to treat PD and will also address the issue of LD delivery as a critical factor for the drug’s propensity to induce motor complications.Keywords: levodopa, motor fluctuations, dyskinesia, Parkinson’s disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Cited by
Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease
Caputi, V., & Giron, M. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061689 · Cited by 338
Xu, X., Wells, A. B., O'Brien, D. R., Nehorai, A., & Dougherty, J. D. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4488-13.2014 · Cited by 282
The Gut-Brain Axis in Parkinson’s Disease: Possibilities for Food-Based Therapies
Perez-Pardo, P., Kliest, T., Dodiya, H. B., Broersen, L. M., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.042 · Cited by 203
St. Laurent, R., O’Brien, L. M., & Ahmad, S. T. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.037 · Cited by 199
Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease
Hou, Y., Li, X., Liu, C., Zhang, M., Zhang, X., Ge, S., & Zhao, L. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111376 · Cited by 101
Metadata
- Authors
- Antonini, A.
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2010-08
- Volume
- 5
- Pages
- 229
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- OpenAlex
- W1998838849
- Cited by
- 250
- References
- 1
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. https://app.cochat.ai/papers/10.2147/cia.s6456
- The paper
- Antonini, A. (2010). Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clinical Interventions in Aging. https://doi.org/10.2147/cia.s6456
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.